These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9212313)

  • 1. Effect of insulin treatment on circulating islet amyloid polypeptide in patients with NIDDM.
    Lindström T; Leckström A; Westermark P; Arnqvist HJ
    Diabet Med; 1997 Jun; 14(6):472-6. PubMed ID: 9212313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in amylin and amylin-like peptide concentrations and beta-cell function in response to sulfonylurea or insulin therapy in NIDDM.
    Rachman J; Payne MJ; Levy JC; Barrow BA; Holman RR; Turner RC
    Diabetes Care; 1998 May; 21(5):810-6. PubMed ID: 9589246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated islet amyloid pancreatic polypeptide and proinsulin in lean gestational diabetes.
    Kautzky-Willer A; Thomaseth K; Ludvik B; Nowotny P; Rabensteiner D; Waldhäusl W; Pacini G; Prager R
    Diabetes; 1997 Apr; 46(4):607-14. PubMed ID: 9075800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Islet amyloid polypeptide (IAPP) secretion from islet cells and its plasma concentration in patients with non-insulin-dependent diabetes mellitus.
    Hanabusa T; Kubo K; Oki C; Nakano Y; Okai K; Sanke T; Nanjo K
    Diabetes Res Clin Pract; 1992 Jan; 15(1):89-96. PubMed ID: 1541240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma concentrations of islet amyloid polypeptide after glucagon administration in type 2 diabetic patients and non-diabetic subjects.
    van Jaarsveld BC; Hackeng WH; Lips CJ; Erkelens DW
    Diabet Med; 1993 May; 10(4):327-30. PubMed ID: 8508614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parallel changes of proinsulin and islet amyloid polypeptide in glucose intolerance.
    MacNamara CM; Barrow BA; Manley SE; Levy JC; Clark A; Turner RC
    Diabetes Res Clin Pract; 2000 Oct; 50(2):117-26. PubMed ID: 10960722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of glipizide gastrointestinal therapeutic system on islet cell hormonal responses to a test meal in NIDDM.
    Mooradian AD; Albert SG; Bernbaum M; Plummer S
    Diabetes Care; 1996 Aug; 19(8):883-4. PubMed ID: 8842609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin-dependent diabetes mellitus.
    Enoki S; Mitsukawa T; Takemura J; Nakazato M; Aburaya J; Toshimori H; Matsukara S
    Diabetes Res Clin Pract; 1992 Jan; 15(1):97-102. PubMed ID: 1541241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No correlation between insulin and islet amyloid polypeptide after stimulation with glucagon-like peptide-1 in type 2 diabetes.
    Ahrén B; Gutniak M
    Eur J Endocrinol; 1997 Dec; 137(6):643-9. PubMed ID: 9437230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased levels of circulating islet amyloid polypeptide in patients with chronic renal failure have no effect on insulin secretion.
    Ludvik B; Clodi M; Kautzky-Willer A; Schuller M; Graf H; Hartter E; Pacini G; Prager R
    J Clin Invest; 1994 Nov; 94(5):2045-50. PubMed ID: 7962550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of oral antidiabetic agents on plasma amylin level in patients with non-insulin-dependent diabetes mellitus (type 2).
    Zapecka-Dubno B; Czyzyk A; Dworak A; Bak MI
    Arzneimittelforschung; 1999 Apr; 49(4):330-4. PubMed ID: 10337452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Islet amyloid polypeptide: a review of its biology and potential roles in the pathogenesis of diabetes mellitus.
    O'Brien TD; Butler PC; Westermark P; Johnson KH
    Vet Pathol; 1993 Jul; 30(4):317-32. PubMed ID: 8212454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased plasma levels of islet amyloid polypeptide in patients with primary hyperparathyroidism.
    Valdermarsson S; Leckström A; Westermark P; Bergenfelz A
    Eur J Endocrinol; 1996 Mar; 134(3):320-5. PubMed ID: 8616529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, safety, and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of two multicenter, randomized, placebo-controlled clinical trials. The Glipizide Gastrointestinal Therapeutic System Study Group.
    Simonson DC; Kourides IA; Feinglos M; Shamoon H; Fischette CT
    Diabetes Care; 1997 Apr; 20(4):597-606. PubMed ID: 9096986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.
    Kumar S; Boulton AJ; Beck-Nielsen H; Berthezene F; Muggeo M; Persson B; Spinas GA; Donoghue S; Lettis S; Stewart-Long P
    Diabetologia; 1996 Jun; 39(6):701-9. PubMed ID: 8781766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma islet amyloid polypeptide (Amylin) levels and their responses to oral glucose in type 2 (non-insulin-dependent) diabetic patients.
    Sanke T; Hanabusa T; Nakano Y; Oki C; Okai K; Nishimura S; Kondo M; Nanjo K
    Diabetologia; 1991 Feb; 34(2):129-32. PubMed ID: 2065848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated mathematical model to assess beta-cell activity during the oral glucose test.
    Thomaseth K; Kautzky-Willer A; Ludvik B; Prager R; Pacini G
    Am J Physiol; 1996 Mar; 270(3 Pt 1):E522-31. PubMed ID: 8638701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of arginine on the secretion of insulin and islet amyloid polypeptide in humans.
    Larsson H; Ahrén B
    Pancreas; 1995 Aug; 11(2):201-5. PubMed ID: 7479680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Islet amyloid polypeptide (IAPP) and pancreatic islet amyloid deposition in diabetic and non-diabetic patients.
    Narita R; Toshimori H; Nakazato M; Kuribayashi T; Toshimori T; Kawabata K; Takahashi K; Masukura S
    Diabetes Res Clin Pract; 1992 Jan; 15(1):3-14. PubMed ID: 1541232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Very high concentrations of islet amyloid polypeptide are necessary to alter the insulin response to intravenous glucose in man.
    Bretherton-Watt D; Gilbey SG; Ghatei MA; Beacham J; Macrae AD; Bloom SR
    J Clin Endocrinol Metab; 1992 May; 74(5):1032-5. PubMed ID: 1569151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.